{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "36434139",
  "DateCompleted": {
    "Year": "2022",
    "Month": "12",
    "Day": "26"
  },
  "DateRevised": {
    "Year": "2023",
    "Month": "02",
    "Day": "13"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2022",
        "Month": "11",
        "Day": "24"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1038/s41568-022-00529-3"
    ],
    "Journal": {
      "ISSN": "1474-1768",
      "JournalIssue": {
        "Volume": "23",
        "Issue": "1",
        "PubDate": {
          "Year": "2023",
          "Month": "Jan"
        }
      },
      "Title": "Nature reviews. Cancer",
      "ISOAbbreviation": "Nat Rev Cancer"
    },
    "ArticleTitle": "The coming decade in precision oncology: six riddles.",
    "Pagination": {
      "StartPage": "43",
      "EndPage": "54",
      "MedlinePgn": "43-54"
    },
    "Abstract": {
      "AbstractText": [
        "High-throughput methods to investigate tumour omic landscapes have quickly catapulted cancer specialists into the precision oncology era. The singular lesson of precision oncology might be that, for it to be precise, treatment must be personalized, as each cancer's complex molecular and immune landscape differs from patient to patient. Transformative therapies include those that are targeted at the sequelae of molecular abnormalities or at immune mechanisms, and, increasingly, pathways previously thought to be undruggable have become druggable. Critical to applying precision medicine is the concept that the right combination of drugs must be chosen for each patient and used at the right stage of the disease. Multiple puzzles remain that complicate therapy choice, including evidence that deleterious mutations are common in normal tissues and non-malignant conditions. The host's role is also likely to be key in determining treatment response, especially for immunotherapy. Indeed, maximizing the impact of immunotherapy will require omic analyses to match the right immune-targeted drugs to the individualized patient and tumour setting. In this Perspective, we discuss six key riddles that must be solved to optimize the application of precision oncology to otherwise lethal malignancies."
      ],
      "CopyrightInformation": "\u00a9 2022. Springer Nature Limited."
    },
    "AuthorList": [
      {
        "Identifier": [
          "0000-0002-8856-8834"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Institute of Metabolism and Cell Death, Helmholtz Zentrum M\u00fcnchen, Neuherberg, Germany. adamwahida@gmail.com."
          },
          {
            "Identifier": [],
            "Affiliation": "Medical Department III for Hematology and Oncology, Klinikum rechts der Isar, TUM School of Medicine, Technical University of Munich, Munich, Germany. adamwahida@gmail.com."
          },
          {
            "Identifier": [],
            "Affiliation": "Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany. adamwahida@gmail.com."
          },
          {
            "Identifier": [],
            "Affiliation": "Division of Gynecological Oncology, National Center for Tumor Diseases (NCT) Heidelberg, Heidelberg, Germany. adamwahida@gmail.com."
          }
        ],
        "LastName": "Wahida",
        "ForeName": "Adam",
        "Initials": "A"
      },
      {
        "Identifier": [
          "0000-0001-7162-816X"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany. lars.buschhorn@med.uni-heidelberg.de."
          },
          {
            "Identifier": [],
            "Affiliation": "Division of Gynecological Oncology, National Center for Tumor Diseases (NCT) Heidelberg, Heidelberg, Germany. lars.buschhorn@med.uni-heidelberg.de."
          }
        ],
        "LastName": "Buschhorn",
        "ForeName": "Lars",
        "Initials": "L"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Division of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg, Heidelberg, Germany."
          },
          {
            "Identifier": [],
            "Affiliation": "German Cancer Consortium (DKTK), Heidelberg, Germany."
          }
        ],
        "LastName": "Fr\u00f6hling",
        "ForeName": "Stefan",
        "Initials": "S"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Division of Clinical Oncology, Department of Medicine, Medical University of Graz, Graz, Austria."
          }
        ],
        "LastName": "Jost",
        "ForeName": "Philipp J",
        "Initials": "PJ"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Division of Gynecological Oncology, National Center for Tumor Diseases (NCT) Heidelberg, Heidelberg, Germany."
          }
        ],
        "LastName": "Schneeweiss",
        "ForeName": "Andreas",
        "Initials": "A"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany."
          },
          {
            "Identifier": [],
            "Affiliation": "German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany."
          },
          {
            "Identifier": [],
            "Affiliation": "National Center for Tumor Diseases (NCT) Heidelberg, Heidelberg, Germany."
          }
        ],
        "LastName": "Lichter",
        "ForeName": "Peter",
        "Initials": "P"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "WIN Consortium, Paris, France. rkurzrock@mcw.edu."
          },
          {
            "Identifier": [],
            "Affiliation": "Medical College of Wisconsin, Milwaukee, WI, USA. rkurzrock@mcw.edu."
          }
        ],
        "LastName": "Kurzrock",
        "ForeName": "Razelle",
        "Initials": "R"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Review",
      "Research Support, Non-U.S. Gov't"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "England",
    "MedlineTA": "Nat Rev Cancer",
    "NlmUniqueID": "101124168",
    "ISSNLinking": "1474-175X"
  },
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "drug therapy",
        "genetics"
      ],
      "DescriptorName": "Neoplasms"
    },
    {
      "QualifierName": [
        "methods"
      ],
      "DescriptorName": "Precision Medicine"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Medical Oncology"
    },
    {
      "QualifierName": [
        "methods"
      ],
      "DescriptorName": "Immunotherapy"
    }
  ]
}